. Author manuscript; available in PMC: 2016 Aug 15.

Published in final edited form as: J Neurol Sci. 2015 May 17;355(0):59–63. doi: 10.1016/j.jns.2015.05.013

Table 1.

Patient demographics

		NMO	MS
Subjects n		26	26
# of Events		28	27
Diagnosis	NMO Seropositive NMO Seronegative NMO	19 (73%) 12 7	N/A
Diagnosis	NMOSD	7 (27%)	N/A
Female sex		22 (85%)	24 (92%)
Age at event (years)	Mean	35.4 range 4.0-67.4	33.6 range 15.2-54.4
Age at event (years)	Median	36.1 years	32.0 years
Race	African American	16 (61%)	9 (35%)
	Caucasian American	7 (27%)	16 (61%)
	Latin American	3 (12%)	1 (4%)
ON as 1^st event (%)		35	61
ON as 1^st event in the affected eye (%)		75	93
# untreated for disease suppression at time of event		23 (82%)	22 (81%)
# MRI obtained prior to acute medication administration		21 (75%)	20 (74%)
Time from first symptom of event to MRI (days)	Mean	10 range 0-30	13 range 2-30
Time from first symptom of event to MRI (days)	Median	5	12